$PFSA

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

HRT FINANCIAL LP purchased 15,924 shares of Profusa, Inc. (PFSA) at an average of $0.96 ($0.95–$0.96) across 2 trades over 2026-08-03 to 2026-08-04.

HRT FINANCIAL LP purchased 9,874 shares of Profusa, Inc. (PFSA) at an average of $1.05 ($1.01–$1.05) across 2 trades over 2026-07-30 to 2026-07-31.

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea030001701ex2-1.htm OPTION AGREEMENT, DATED JULY 31, 2026, BY AND AMONG PROFUSA, INC Exhibit 2.1 OPTION AGREEMENT This Option Agreement (this “ Agreement ”) is made and entered into as of July 31, 2026, by and among Profusa, Inc., a Delaware corporation (the “ Buyer ”),

HRT FINANCIAL LP purchased 1,310 shares of Profusa, Inc. (PFSA) at $1.01 on 2026-07-29.

Profusa (NASDAQ:PFSA) signed a non-binding term sheet to acquire a commercial-stage diagnostics company. The target estimates unaudited 2025 net revenue of about $111 million. Profusa plans to operate national CLIA-certified labs and expects about $7 million in financing. It appointed Jack Stover as CEO and Executive Chairman, with Ben Hwang becoming President.

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.

Profusa, Inc. (NVACW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001859807 0001859807 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Profusa, Inc. (PFSA) will conduct a 1-for-25 reverse stock split effective July 7, 2026, keeping the PFSA ticker. The company says shares outstanding will fall from about 13.2M to ~530,000; par value and shareholder rights are unchanged aside from share count. Fractional shares won’t be issued; cash will be paid in lieu. PFSA closed at $0.09 (-28.08%).